FibroGen Reports Dose-finding Data from Phase 2b Study of FG-4592 for Anemia ... Business Wire (press release) ... dose-finding study of FG-4592, an investigational hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), for anemia correction and hemoglobin (Hb) maintenance in patients with stage 3 or 4 chronic kidney disease (CKD) not on dialysis. ... FibroGen Reports Dose-finding Data from Phase 2b Study of FG-4592 for Anemia ... |
